Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231208 | 0.86 | ALDH1A1 (0.68) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL7221288 | 0.86 | MMP1 (0.55) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL7389327 | 0.86 | CA1 (0.66) | RAB9AALDH1A1NPC1MAPTMEN1 | |
| SCHEMBL11336785 | 0.86 | POLB (0.61) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| Methane SCHEMBL11380092 | 0.84 | ALDH1A1 (0.66) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL28483353 | 0.83 | ALDH1A1 (0.73) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL4687356 | 0.83 | MAPT (0.62) | SMN1; SMN2RAB9ATSHRMAPTMEN1 | |
| SCHEMBL13949637 | 0.83 | RAB9A (0.51) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL11021070 | 0.83 | TSHR (0.76) | SMN1; SMN2RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL23014298 | 0.81 | RAB9A (0.61) | SMN1; SMN2RAB9AALDH1A1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | SMN1; SMN2 4794/4885RAB9A 2123/4885ALDH1A1 1249/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | SMN1; SMN2 4794/4885RAB9A 2123/4885ALDH1A1 1249/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | SMN1; SMN2 4794/4885RAB9A 2123/4885ALDH1A1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.